Actively Recruiting
Aspirin vs Clopidogrel After TAVR
Led by Yonsei University · Updated on 2026-01-07
254
Participants Needed
1
Research Sites
232 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Currently, the optimal antithrombotic therapy after transcatheter aortic valve replacement (TAVR) remains still unknown., The purpose of the study is to compare aspirin versus clopidogrel monoantiplatelet therapy for preventive effect on leaflet thrombosis in patients undergoing TAVR for severe aortic stenosis. This study is designed as a prospective, multicenter, open label, randomized controlled study. Eligible patients will be randomized to aspirin or clopidogrel monotherapy after TAVR. Patients will have dual antiplatelet therapy of aspirin 100 mg and clopidogrel 75 mg for 4 weeks after TAVR and then subsequent monoantiplatelet therapy of either aspirin 100 mg or clopidogrel 75 mg according to the randomization. Leaflet thrombosis will be assessed with cardiac computed tomography (CT) and transthoracic echocardiography at 3 months after TAVR. Patients will be clinically followed for 6 months. The primary endpoint is the Incidence of leaflet thrombosis on cardiac CT at 3 months.
CONDITIONS
Official Title
Aspirin vs Clopidogrel After TAVR
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 19 years
- Patients who have undergone transcatheter aortic valve replacement for symptomatic severe aortic stenosis
- Willingness to provide informed consent
You will not qualify if you...
- Need for dual antiplatelet therapy longer than 4 weeks
- Conditions requiring specific antiplatelet therapy with aspirin or clopidogrel
- History of stroke or transient ischemic attack within 6 months
- Planned major surgery
- Cardiogenic shock or hemodynamic instability
- Chronic kidney disease stage 4 or 5 (eGFR less than 30 mL/min)
- Valve-in-valve TAVR procedure
- Allergy or contraindication to aspirin or clopidogrel
- Requirement for anticoagulation therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Actively Recruiting
Research Team
Y
Young-Guk Ko, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here